Kisspeptin-54
Metastin, KP-54, Kisspeptin-1 (68-121), KISS1-derived 54-residue peptide
Kisspeptin-54 is a naturally occurring human peptide, encoded by the KISS1 gene, that acts as the master upstream trigger of GnRH release. It is not a licensed medicine anywhere. Its therapeutic interest lies in stimulating the reproductive axis one step above GnRH, which has been tested as a gentler ovulation trigger in IVF for women at high risk of ovarian hyperstimulation syndrome.
Mechanism
Kisspeptin-54 is the longest of several bioactive fragments cleaved from the KISS1 precursor protein; shorter fragments including kisspeptin-14, kisspeptin-13 and kisspeptin-10 share the same C-terminal decapeptide, which is the portion essential for receptor binding. All signal through KISS1R (formerly GPR54), a Gq-coupled receptor expressed densely on hypothalamic GnRH neurons. Receptor activation drives phospholipase C signalling, intracellular calcium mobilisation and depolarisation of the GnRH neuron, causing GnRH release into the hypophyseal portal circulation and, downstream, LH and FSH secretion from the pituitary.
The physiological importance of this pathway was established by human genetics rather than by pharmacology. Loss-of-function mutations in KISS1R cause normosmic isolated hypogonadotrophic hypogonadism. Affected individuals fail to enter puberty despite an intact GnRH neuron population and a pituitary capable of responding to exogenous GnRH. That phenotype identified kisspeptin signalling as an obligatory gatekeeper of reproductive function. Kisspeptin neurons in the arcuate nucleus, co-expressing neurokinin B and dynorphin, are now understood to contribute to generation of the GnRH pulse rhythm itself, while a separate population in the anteroventral periventricular region mediates the oestrogen-driven positive feedback that produces the preovulatory LH surge. Kisspeptin neurons also integrate metabolic and stress signals, which is thought to explain how energy deficit and psychological stress suppress reproduction in conditions such as functional hypothalamic amenorrhoea.
The therapeutic hypothesis follows from acting one step upstream. Because kisspeptin stimulates the patient's own GnRH neurons rather than bypassing them, the resulting LH surge is physiological in shape and self-limiting, unlike the sustained stimulus of a conventional human chorionic gonadotrophin trigger, which drives the prolonged luteal stimulation implicated in ovarian hyperstimulation syndrome.
What the research shows
The most substantial clinical work comes from a research group in London. In a proof-of-concept study, 53 women undergoing IVF received a single subcutaneous injection of kisspeptin-54 to trigger final oocyte maturation after recombinant FSH stimulation with GnRH antagonist cover. Egg maturation occurred at every dose tested; fertilisation and embryo transfer proceeded in 92 per cent of women, with a biochemical pregnancy rate of 40 per cent and a clinical pregnancy rate of 23 per cent. A follow-up study specifically enrolled 60 women at high risk of ovarian hyperstimulation syndrome and found kisspeptin-54 could trigger oocyte maturation in that population, which is where a self-limiting trigger would be most valuable. These are genuinely interesting results, but they are uncontrolled or dose-ranging in design, single-centre, and the pregnancy rates are not directly comparable to those of standard triggers without a randomised head-to-head trial, which has not been done at scale.
A separate line of work examined kisspeptin-54 in women with hypothalamic amenorrhoea, a condition characterised by deficient LH pulsatility. In a single-blinded controlled crossover study, five women each attended six visits receiving eight-hour infusions of vehicle or one of five kisspeptin-54 doses. CORRECTION ON AUDIT: the draft reported a fivefold increase in LH pulsatility, which does not match the published abstract. The paper reports that the mean peak number of LH pulses was threefold higher with kisspeptin-54 than vehicle (5.0 versus 1.6 pulses per 8 hours) and that the mean peak LH pulse secretory mass was sixfold higher (23.44 versus 3.92 IU/L). The same body of work exposed the central limitation: chronic kisspeptin-54 administration causes tachyphylaxis, with the response attenuating on repeated or prolonged exposure. This is mechanistically unsurprising (sustained Gq-coupled receptor stimulation leads to desensitisation, the same phenomenon exploited deliberately by GnRH agonists), but it constrains kisspeptin-54 to acute applications such as a single ovulation trigger rather than ongoing treatment of chronic anovulation.
Evidence assessment
Limited evidence
DOWNGRADED FROM "mixed" ON AUDIT. "Mixed" implies conflicting human results; the kisspeptin-54 human data are not conflicting, they are simply sparse. The three surviving citations are an uncontrolled dose-ranging study in 53 women, an early-phase study in 60 women, and a crossover mechanistic study in just five women, all from essentially one research group at one centre in London. There is no phase 3 trial, no randomised comparison against a standard ovulation trigger, no independent replication at scale, and no regulatory approval in any jurisdiction. The underlying physiology is exceptionally well established, since human genetics alone proves kisspeptin signalling is essential for reproduction, but physiological certainty is not therapeutic evidence and must not be allowed to inflate the tier. Small, single-centre, uncontrolled human studies with no approval is squarely limited.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization Preclinical only
Oocyte maturation occurred at every dose tested. Fertilisation and embryo transfer proceeded in 92 per cent of women, with biochemical pregnancy in 40 per cent and clinical pregnancy in 23 per cent. No randomised comparator against a standard trigger.
Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy Preclinical only
Kisspeptin-54 triggered oocyte maturation in a population at high risk of ovarian hyperstimulation syndrome. With 60 participants and no randomised standard-trigger comparator, the study cannot establish a comparative safety advantage.
Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of Kisspeptin-54 Preclinical only
Mean peak number of LH pulses was threefold higher with kisspeptin-54 than vehicle (5.0 versus 1.6 per 8 hours, P<0.01) and mean peak LH pulse secretory mass sixfold higher (23.44 versus 3.92 IU/L, P<0.05). Optimal dose differed between individuals. Establishes the physiology; far too small for therapeutic conclusions.
Safety
Human safety data are limited to a few hundred participants at most across small early-phase studies, so the profile should be regarded as incompletely characterised rather than reassuring. Within those studies kisspeptin-54 has been reported as well tolerated, with no consistent pattern of serious adverse events. Because kisspeptin acts upstream of GnRH and produces a self-limiting physiological surge, the theoretical hazard profile differs from that of a sustained human chorionic gonadotrophin trigger, but this is a mechanistic argument rather than a demonstrated safety advantage, and no adequately powered randomised comparison has tested it. Tachyphylaxis on repeated dosing is a documented pharmacodynamic limitation. Kisspeptin-54 is not approved by any regulator, so any material offered for human use outside a clinical trial is unlicensed and falls outside pharmaceutical quality control. Identity, purity, sterility and actual peptide content are unverified, which is a substantive hazard independent of the molecule itself. The KISS1 gene was originally identified as a metastasis suppressor, and the biology of kisspeptin signalling in tumour tissue is complex and not fully resolved; the long-term consequences of pharmacological kisspeptin exposure have not been studied.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. Kisspeptin-54 remains an investigational medicinal product, studied in the United Kingdom under clinical trial authorisations, principally by academic groups in London. |
| United States | Not approved by the FDA for any indication. Kisspeptin-54 has been used in the United States and elsewhere only under investigational protocols. It is not a dietary supplement ingredient and has no legal route to human sale. |
| WADA (sport) | Not named individually on the WADA Prohibited List. However, section S2 prohibits releasing factors for luteinising hormone in male athletes, and kisspeptin functions precisely as such a releasing factor. Athletes should treat its status as unresolved and seek guidance from their anti-doping organisation rather than assume it is permitted. |
Questions
From genetics rather than drug trials. People born with loss-of-function mutations in the kisspeptin receptor KISS1R fail to enter puberty, despite having intact GnRH neurons and a pituitary that responds normally to exogenous GnRH. That natural experiment establishes kisspeptin signalling as an obligatory gatekeeper of the reproductive axis.
The reasoning is mechanistic. Kisspeptin stimulates the patient's own GnRH neurons, producing a physiological, self-limiting LH surge. A conventional human chorionic gonadotrophin trigger provides a sustained stimulus that drives prolonged luteal activity, which is implicated in ovarian hyperstimulation syndrome. Early studies in high-risk women are consistent with this, but no adequately powered randomised comparison against standard triggers has been done.
Limited. Three small studies from essentially one research group at one centre, the largest with 60 participants and the most mechanistically informative with just five. None randomised kisspeptin against a standard trigger. The physiology is beyond doubt; the therapeutic case is not yet made.
No. It is not approved by any regulator anywhere in the world, and it has only ever been given to humans within clinical trials. Anything sold as kisspeptin-54 outside a trial is unlicensed material of unverified identity, purity and sterility.
Because the receptor desensitises. Studies in women with hypothalamic amenorrhoea showed a strong acute increase in LH pulsatility but attenuation of the response on chronic administration. This is the same tachyphylaxis that GnRH agonists exploit deliberately to shut the axis down, and it limits kisspeptin-54 to acute applications such as a single trigger.
They are different-length fragments of the same precursor protein sharing the identical C-terminal decapeptide that binds the receptor. Kisspeptin-54 is the longer, naturally circulating form with a somewhat longer duration of action, whereas kisspeptin-10 is the minimal active sequence and clears more rapidly.